[HTML] springer.comFull View

[HTML][HTML] Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - Springer
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …
被引用次数：145 相关文章

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists.

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - search.ebscohost.com
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - go.gale.com
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …

[引用][C] Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - cir.nii.ac.jp
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[PDF] researchgate.net

[PDF][PDF] Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - 2014 - researchgate.net
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - search.proquest.com
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …
[HTML] biomedcentral.com

[HTML][HTML] Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - cardiab.biomedcentral.com
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …
[HTML] nih.gov

[HTML][HTML] Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - ncbi.nlm.nih.gov
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists.

FK Saraiva, AC Sposito - Cardiovascular Diabetology, 2014 - europepmc.org
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

FK Saraiva, AC Sposito - Cardiovascular diabetology, 2014 - pubmed.ncbi.nlm.nih.gov
Patients with type 2 diabetes have a several-fold increased risk of developing
cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and …